Skip to main content
Herbert Lyerly, MD, General Surgery, Durham, NC

HerbertLyerlyMDFACS

General Surgery Durham, NC

George Barth Geller Professor of Cancer Research Professor, Surgery, Immunology, and Pathology, Duke University School of Medicine

Dr. Lyerly is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Lyerly's full profile

Already have an account?

  • Office

    2100 Erwin Rd
    Durham, NC 27705
    Phone+1 919-620-4467

Education & Training

  • Duke University Hospital
    Duke University HospitalResidency, Surgery, 1983 - 1990
  • David Geffen School of Medicine at UCLA
    David Geffen School of Medicine at UCLAClass of 1983
  • University of California, Riverside
    University of California, RiversideBS, Biomedical Sciences, Summa Cum Laude, 1980

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 1990 - 2025
  • American Board of Surgery Surgery

Awards, Honors, & Recognition

  • National Cancer Advisory Board National Cancer Institute, 2008-2014
  • Director’s Service Award National Cancer Institute, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling  
    Pruszynski M, Koumarianou E, Vaidyanathan G, Revets H, Devoogdt N, Lahoutte T, Lyerly HK, Zalutsky MR, J Nucl Med, 4/1/2014
  • Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer  
    Sandip P. Patel, Takuya Osada, Koya Osada, Herbert Hurwitz, H. Kim Lyerly & Michael A. Morse, Curr Colorectal Cancer Rep, 8/13/2013
  • A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resec...  
    Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, Osada T, Onaitis M, Clary BM, Hsu D, Devi GR, Bul..., Ann Surg, 5/1/2013
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Increased disease-free survival following adoptive transfer of tumor-specific T lymphocytes to mice with breast cancer
    Coveney E, Clary BM, Philip R, Lyerly HK, 82nd Clinical Congress of the American College of Surgeons, 10/1/1996
  • Active immunotherapy of pancreatic cancer with IFN and IL2 secreting tumor cell vaccinations
    Clary BM, Coveney EC, Blazer DG III, Philip R, Gilboa E, Lyerly HK, The North Carolina Chapter of the American College of Surgeons, Resident’s Forum, 7/1/1996
  • Generation of IL-2 gene transduced breast cancer cells for use in active specific immunotherapy
    Clary BM, Philip R, Coveney EC, Philip M, Gilboa E, and Lyerly HK, 18th Annual Breast Cancer Symposium, 12/1/1995
  • Join now to see all

Press Mentions

  • Why Doctors Almost Never Say Cancer Is ‘Cured’
    Why Doctors Almost Never Say Cancer Is ‘Cured’April 22nd, 2022
  • Promising Cancer Vaccine in the Works Utilizing Similar mRNA Technology That Combats COVID: Duke Researchers
    Promising Cancer Vaccine in the Works Utilizing Similar mRNA Technology That Combats COVID: Duke ResearchersApril 15th, 2022
  • mRNA Vaccines: How COVID Jab Tech Will Teach Our Bodies to Kill Cancer
    mRNA Vaccines: How COVID Jab Tech Will Teach Our Bodies to Kill CancerJanuary 25th, 2022
  • Join now to see all

Professional Memberships